Hui Zhao
Senior Director, Translational Biology Exelixis, Inc.
Seminars
Wednesday 14th October 2026
Presentation Preview: Exploring Design & Preclinical Characterization of XB773, a Novel Anti-DLL3 Targeting ADC
- Evaluating rationale for targeting DLL3 with an ADC, laying out selective overexpression in SCLC and neuroendocrine cancers
- Describing design and development of XB773 highlighting humanized VHH Fc antibody conjugated to Topo1 payload via AJICAP conjugation
- Laying out preclinical characterization across in vitro cytotoxicity and internalization and in vivo efficacy in CDX and PDX models
